ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2015

Feb 18, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2015-02-17

Reporting Person: MedImmune Ventures, Inc. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	188912	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series AA Convertible Preferred Stock	$		Common Stock (1255123)		Direct
Convertible Promissory Notes	$		Common Stock (57204)		Direct

Footnotes

F1: The Series AA Convertible Preferred Stock ("Series AA Preferred") is convertible at any time at the holder's election and has no expiration date. All shares of Series AA Preferred, including all accrued and unpaid dividends thereon, will be automatically converted on a 4.05783-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The number of shares of Common Stock as shown in column 3 is based on a conversion of 4,013,692 shares of Series AA Preferred held directly by MedImmune Ventures, Inc., plus accrued and unpaid dividends on each share of Series AA Preferred through the assumed closing date of February 23, 2015.

F2: The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes will be automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes have no expiration date. The number of shares of Common Stock as shown in column 3 is based on a conversion of $338,551.12 of principal amount of Convertible Promissory Notes, plus accrued and unpaid interest through the assumed closing date of February 23, 2015.